HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hormone replacement therapy in children with hypogonadotropic hypogonadism: where do we stand?

AbstractOBJECTIVE:
To characterize hormone replacement therapy in a cohort of adolescent males and females with hypogonadotropic hypogonadism (HH) with a focus on changes in management during the past 10 years.
METHODS:
Medical records of patients followed for HH during the past 10 years were reviewed.
RESULTS:
A total of 45 patients (22 female: 23 male) with HH were identified. The average age at HH diagnosis was 14.48 ± 2.02 years in females and 14.89 ± 1.64 years in males (P = .53). In females, the average age of pubertal induction was 14.53 ± 1.86 years. Conjugated equine estrogen was used in 54.5%, transdermal estradiol in 41%, and oral estradiol in 4.5%. The average duration to cycling was 1.96 ± 0.78 years. A progressive increase in the use of transdermal estradiol was noted over time, with 100% of females being started on this regimen since 2008. In males, the average age of induction was 15.22 ± 1.41 years. All were started on intramuscular testosterone cypionate at various doses. The average duration to full adult replacement was 1.95 ± 0.51 years.
CONCLUSION:
There is no current standard of care to guide pubertal induction in adolescents with HH. However, a significant increase in the use of transdermal estrogen was noted in females during the past 10 years. While much less variability in pubertal induction was seen in males, wide disparities in doses and escalation schedules were found. Prospective studies aimed at elucidating optimal strategies for sex steroid replacement in this pediatric population are badly needed.
AuthorsZeina Nabhan, Erica A Eugster
JournalEndocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists (Endocr Pract) 2013 Nov-Dec Vol. 19 Issue 6 Pg. 968-71 ISSN: 1934-2403 [Electronic] United States
PMID23807524 (Publication Type: Journal Article)
Chemical References
  • Delayed-Action Preparations
  • Gonadotropins
  • Gonadotropins, Equine
  • Testosterone
  • Progesterone
  • Estradiol
  • testosterone 17 beta-cypionate
Topics
  • Administration, Cutaneous
  • Adolescent
  • Age of Onset
  • Cohort Studies
  • Delayed-Action Preparations
  • Dose-Response Relationship, Drug
  • Estradiol (therapeutic use)
  • Female
  • Gonadotropins (deficiency)
  • Gonadotropins, Equine (therapeutic use)
  • Hormone Replacement Therapy (methods)
  • Humans
  • Hypogonadism (drug therapy)
  • Hypopituitarism (complications)
  • Injections, Intramuscular
  • Male
  • Progesterone (administration & dosage, therapeutic use)
  • Puberty
  • Testosterone (administration & dosage, analogs & derivatives, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: